Ligands for Alpha-4-Beta-1 Integrin

Tech ID: 11318 / UC Case 2004-325-0

Abstract

Alpha-4 beta-1 ligands as targeting agents for cancer and autoimmune diseases

Full Description

Highly potent ligands for activated alpha-4 beta-1 integrin have been identified by University of California, Davis researchers. These ligands can potentially be used as targeting agents for cancer as well as anti-inflammatory agents for autoimmune diseases.

Notable applications of these alpha-4 beta-1 ligands include:

  • Targeting therapy for imaging of cancers including lymphoid malignancies, which have high level of activated alpha-4 beta-1 integrin on the cell surface;
  • Therapeutic uses as anti-inflammatory agents for autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and lupus; and,
  • Treatment of both human and dog diseases listed above.

The compounds for activated alpha-4 beta-1 integrin of the present invention have high affinity to human malignant lymphoid cells (both T- and B-cells, and including fresh malignant cells from patients with acute lymphocytic leukemia). Importantly, the binding affinities of these ligands are much higher than products currently developed.

Related Materials

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 8,486,370 07/16/2013 2007-154
United States Of America Issued Patent 7,576,175 08/18/2009 2004-325
 

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Lam, Kit S.
  • Liu, Ruiwu
  • Peng, Li

Other Information

Categorized As